$3.39
-0.06 (-1.74%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CTMX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 3 with posted results
Held by 9 tracked-famous managers (Point72 Asset Management, L.P., TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, Qube Research & Technologies Ltd, +4 more) · FINRA short interest 11.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| First In Human Study of CX-801 in Advanced Solid TumorsNCT06462794Safety and tolerability of CX-801 as monotherapy and combination therapyNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CX-801, pembrolizumab | Solid Tumor, Adult | 121 | 2028-02-28 | in 558 d | 2026-06-29 |
| First In Human Study of CX-2051 in Advanced Solid TumorsNCT06265688Safety and tolerability of CX-2051Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CX-2051, Bevacizumab | Solid Tumor, Adult | 160 | 2027-11-30 | in 468 d | 2026-07-15 |
| A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid TumorsNCT05387265Patients Experiencing Dose-limiting ToxicityOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: CX-904 | Solid Tumors | 83 | 2025-06-04actual | — | 2025-07-14 |
| Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast CancerNCT04596150Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: CX-2009, CX-072 | Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative | 125 | 2023-06-02actual | — | 2024-01-23 |
| PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLNCT03543813The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapyNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: CX-2029 | Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer | 133 | 2023-06-01actual | — | 2024-01-23 |
| PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid TumorsNCT03706274The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-188 as a monotherapyNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: CX-188 | Solid Tumor, Adult | 0 | Dec 2020 | — | 2021-05-05 |
| PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasNCT03013491results2025-06-17The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or VemurafenibNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: CX-072, ipilimumab, vemurafenib | Solid Tumor, Lymphoma | 196 | 2020-10-27actual | — | 2025-06-17 |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid TumorsNCT03149549results2024-01-05The Number of Subjects Experiencing a Dose Limiting Toxicity at Various Dose Levels When Given CX-2009 as a MonotherapyNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Covid Pandemic; Business Decision to separate Phase 2 to new study | Drug: CX-2009 | Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer | 99 | 2020-09-10actual | — | 2024-01-05 |
| PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsNCT03993379results2021-12-01Overall Response Rate by RECIST v 1.1Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor's Decision | Drug: CX-072, Ipilimumab | Solid Tumor, Unresectable or Metastatic Melanoma | 3 | 2020-05-21actual | — | 2025-12-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19